Sign in to continue:

Friday, March 20th, 2026

The Glimpse Group, Inc. Files Form 8-K with SEC – Key Company Information and Filing Details

The Glimpse Group, Inc. Receives Nasdaq Delisting Notice: What Investors Need to Know

Key Developments:

  • Nasdaq Minimum Bid Price Deficiency Notice: On March 13, 2026, The Glimpse Group, Inc. (the “Company”) received a formal notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department stating that the Company’s common stock had closed below the minimum bid price of \$1.00 per share for 30 consecutive business days.
  • Current Listing Status: This notice means that the Company is no longer in compliance with Nasdaq Marketplace Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of \$1.00 per share.

Details and Timeline for Compliance:

  • No Immediate Delisting: The receipt of this notice has no immediate effect on the listing or trading of Glimpse Group’s common stock, which will continue to trade under the ticker symbol GGRP on the Nasdaq Capital Market.
  • Compliance Period: The Company has 180 calendar days (until September 9, 2026) to regain compliance. To do so, the closing bid price of the Company’s common stock must meet or exceed \$1.00 per share for at least 10 consecutive business days during this period.
  • Potential for Additional Time: If the Company does not regain compliance by September 9, 2026, it may be eligible for an additional 180-day grace period, provided it meets the continued listing requirements for market value of publicly held shares and all other initial listing standards (except the bid price requirement). The Company must also notify Nasdaq in writing of its plan to regain compliance, which may include actions such as a reverse stock split.
  • Risk of Delisting: If the Company cannot demonstrate compliance, or if Nasdaq staff determines it will not be able to cure the deficiency, the Company’s securities will be subject to delisting from the Nasdaq Capital Market.

Implications for Shareholders:

  • Share Price Volatility: Notices of non-compliance and potential delisting can create significant uncertainty and may lead to increased volatility or downward pressure on the Company’s share price.
  • Remedial Actions: The Company’s Board of Directors is actively considering all available options to resolve the deficiency and maximize shareholder value. This could include a reverse stock split or other corporate actions, which can have significant effects on shareholder equity and price per share.
  • No Impact on Business Operations: The notice does not impact the Company’s business operations, ongoing projects, or SEC reporting requirements at this time.
  • Emerging Growth Company: The Glimpse Group is classified as an “Emerging Growth Company,” which allows it certain regulatory accommodations; however, it has not opted out of the extended transition period for complying with new or revised financial accounting standards.

What Investors Should Watch For:

  • Any announcement of actions to cure the deficiency, such as a reverse stock split or other measures, will be highly relevant and potentially price-sensitive.
  • Shareholders should monitor the Company’s ability to restore compliance within the Nasdaq’s timeframe.
  • Failure to regain compliance could lead to delisting, which may significantly impact liquidity, trading volume, and institutional investor participation.

Company Details:

  • Name: The Glimpse Group, Inc.
  • Ticker: GGRP
  • Exchange: Nasdaq Capital Market
  • Headquarters: 15 West 38th St., 12th Floor, New York, NY 10018
  • Industry: Computer Programming Services (Technology)
  • Fiscal Year End: June 30

Disclaimer: This article is for informational purposes only and is not investment advice. Investors should conduct their own due diligence or consult with a qualified financial advisor before making any investment decisions. The information herein is based on public filings and may be subject to change without notice.

View Glimpse Group, Inc. Historical chart here



System1, Inc. Releases Q4 2025 Supplemental Financial Information and Performance Metrics

System1, Inc. Releases Fourth Quarter and Full Year 2025 Sup...

ORIC Pharmaceuticals, Inc. Form 8-K Filing Details and XBRL Entity Information (Feb 23, 2026)

ORIC Pharmaceuticals Files Prospectus Supplement for Up to \...

Calavo Growers, Inc. Q1 2026 Financial Report: Risks, Merger, and Key Financials

Calavo Growers, Inc. Releases Q1 2026 Financial Results: Key...

   Ad